Status:
TERMINATED
Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED
Lead Sponsor:
Massachusetts General Hospital
Conditions:
COVID19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respiratory complaints, with many of these patients requi...
Detailed Description
The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respiratory complaints, with many of these patients requi...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Presentation to the ED with respiratory symptoms likely caused by COVID-19
- Patient displays at least one of the following
- respiratory rate ≥ 24
- new cough
- new atypical chest pain
- new dyspnea
- oxygen saturation \< 97% at rest
- chest x-ray with new changes consistent with COVID-related airspace disease
- Cleared for discharge home by attending physician
- Obtained COVID testing (results not required at time of enrollment)
- Onset of symptoms ≤12 days prior to ED visit
Exclusion
- Attending physician estimation (\< 50% likelihood) of other more likely non-COVID etiology
- Presence of tracheostomy
- Requirement of oxygen therapy to maintain resting oxygen saturation of \> 94%
- Clinical contraindication to use of inhaled nitric oxide
Key Trial Info
Start Date :
April 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04338828
Start Date
April 18 2020
End Date
March 1 2021
Last Update
January 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114